RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1
acquisition. The prespecified analysis of immune correlates of risk showed that antibodies …

Twenty years after the discovery of HIV, there is still no vaccine. This year, an envelope
vaccine aimed at stimulating neutralizing antibodies was unable to protect against infection …

ABSTRACT A major problem hampering the development of an effective vaccine against
human immunodeficiency virus type 1 (HIV-1) is the resistance of many primary viral isolates …

The twenty-first century has begun with considerable success for new AIDS vaccines in
macaque models. A common feature of these vaccines is their ability to induce high …

The functional unit of the human immunodeficiency virus type 1 (HIV-1) envelope
glycoproteins is a trimer composed of three gp120 exterior glycoproteins and three gp41 …

The following problem is treated: given s possibly selection biased samples from an
unknown distribution function, and assuming that the sampling rule weight functions for each …

Successful vaccination programs, particularly against inffuenza virus infection, have
provided us with an awareness of the need to immunize against the predominant circulating …

To help to design vaccines for acquired immune deficiency syndrome that protect broadly
against many genetic variants of the human immunodeficiency virus, the mutation rates at …

Last year, President Clinton made clear the urgent need for an effective HIV vaccine, and
suggested that it should be possible to create one within ten years. The authors agree …

This article reviews advances in the field of human immunodeficiency virus type 1 (HIV-1)
and AIDS vaccine development over the last decade, with an emphasis on the DNA …